Nové číslo účtu FN Brno od 1.12.2016 je 712 346 21/0710. Více informací

Onkologie - publikace


Cross NC, White HE, Ernst T, et al. Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. Leukemia.2016;30(9):1844-1852.

Culen M, Borsky M, Nemethova V, et al. Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects. Oncotarget. 2016;7(22):33016-33024.

Jeziskova I, Semerad L, Dvorakova D, et al. Novel complex mutation in NPM1 gene in patient with acute myeloid leukemia. Leuk Lymphoma. 2016; Aug 3:1-3. [Epub ahead of print]

Pettersson L, Leveen P, Axler O, Dvorakova D, Juliusson G, Ehinger M. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia. Genes Chromosomes Cancer. 2016;55(10):750-766.

Cetkovský, P. Mayer, J., Starý, J, Hričinová, M. et al. (Eds.):, Transplantace kostní dřeně a periferních hematopoetických buněk. Galén, Praha, 2016


Jeziskova I, Musilova M, Culen M, et al. Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML. Int J Hematol. 2015;102(5):553-557.

Robesova B, Bajerova M, Hausnerova J, Skrickova J, Tomiskova M, Dvorakova D. Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC. Lung Cancer. 2015;87(3):318-320.

Sustkova Z, Jeziskova I, Dvorakova D, et al. Limited efficacy of HLA-haploidentical peripheral blood stem cell infusion in treatment of elderly patients with acute myelogenous leukaemia. Hematol Oncol. 2015; Aug 27. doi: 10.1002/hon.2254. [Epub ahead of print]

White H, Deprez L, Corbisier P, et al. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR.Leukemia.2015;29(2):369-376.


Jurcek T, Razga F, Mazancova P, et al. Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34 + cells of patients with de novo chronic myeloid leukemia. Leuk Lymphoma. 2014;55(8):1915-1917.

Musilova M, Razga F, Jurcek T, et al. BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing. Am J Hematol. 2014;89(10):1016-1017.

Robesova B, Bajerova M, Liskova K, et al. TaqMan based real time PCR assay targeting EML4-ALK fusion transcripts in NSCLC. Lung Cancer. 2014;85(1):25-30.

Volfova P, Lengerova M, Lochmanova J, et al. Detecting human cytomegalovirus drug resistant mutations and monitoring the emergence of resistant strains using real-time PCR. J Clin Virol. 2014;61(2):270-274.


Dvorakova D, Racil Z, Borsky M, et al. Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations. Leuk Lymphoma. 2013;54(5):1056-1060.

Jeziskova I, Razga F, Toskova M, et al. Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene. Leuk Lymphoma. 2013;54(4):867-870.

Pospíšilová, Š., Dvořáková, D., Mayer J. (Eds.): Molekulární hematologie. Galén, Praha, 2013.

Klamova H, Polakova KM, Muzik J, et al. Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels. Cancer Med. 2013;2(2):216-225.

Klampfl T, Milosevic JD, Puda A, et al. Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. PLoS One. 2013;8(10):e77819.

Malcikova J, Razga F, Jurcek T, et al. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. Leuk Lymphoma. 2013;54(9):2083-2087.

Robesova B, Bajerova M, Vasikova A, et al. [Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - laboratory experience]. Klin Onkol. 2013;26(1):25-30.

Szturz P, Hlavaty L, Prasek J, Dvorakova D. Erdheim-Chester disease and Schnitzler syndrome: so near, and yet so far. Int J Hematol. 2013;98(4):379-381.

Zackova D, Klamova H, Muzik J, et al. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials. Leuk Lymphoma. 2013;54(10):2310-2313.


Janikova A, Mareckova A, Dvorakova D, et al. A real-time (PCR) for a real life...? Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice. Exp Hematol. 2012;40(7):528-539.e524.

Milosevic JD, Puda A, Malcovati L, et al. Clinical significance of genetic aberrations in secondary acute myeloid leukemia. Am J Hematol. 2012;87(11):1010-1016.

Racil Z, Toskova M, Dvorakova D, et al. Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy. Am J Hematol. 2012;87(2):211-213.

Razga F, Jurcek T, Jeziskova I, et al. Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood. Mol Diagn Ther. 2012;16(3):163-166.

Razga F, Jurcek T, Zackova D, et al. Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations. Mol Diagn Ther. 2012;16(4):251-259.

Simara P, Peterkova M, Stejskal S, et al. BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response. Leuk Lymphoma. 2012;53(8):1627-1629.

Volfova P, Lengerova M, Winterova J, Racil Z, Dvorakova D, Mayer J. Monitoring of Epstein-Barr virus load in patients after allogeneic hematopoietic stem cell transplantation. Infection. 2012;40(5):583-587.


Horky O, Mayer J, Kablaskova L, et al. Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse. Int J Lab Hematol. 2011;33(1):57-66.

Krejci M, Brychtova Y, Doubek M, et al. Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Neoplasma. 2011;58(5):406-414.

Racil Z, Razga F, Polakova KM, et al. Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types. Leuk Lymphoma. 2011;52(2):331-334.

Razga F, Racil Z, Machova Polakova K, et al. The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia. Int J Hematol. 2011;94(3):303-306.

Volfova P, Lengerova M, Dvorakova D, et al. [Role of PCR detection and quantification of herpes viruses in bronchoalveolar lavage of immunocompromised patients]. Klin Mikrobiol Infekc Lek. 2011;17(6):194-200.

Zackova D, Klamova H, Dusek L, et al. Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials? Am J Hematol. 2011;86(3):318-321.


Dvorakova D, Racil Z, Jeziskova I, et al. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations. Am J Hematol. 2010;85(12):926-929.

Jeziskova I, Razga F, Bajerova M, Racil Z, Mayer J, Dvorakova D. IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status. Leuk Lymphoma. 2010;51(12):2285-2287.

Jeziskova I, Razga F, Gazdova J, et al. A case of a novel PML/RARA short fusion transcript with truncated transcription variant 2 of the RARA gene. Mol Diagn Ther. 2010;14(2):113-117.

Jurcek T, Razga F, Jeziskova I, et al. Failure of molecular diagnostics in chronic myeloid leukemia: an aberrant form of e13a2 BCR-ABL transcript causing false-negative results by standard polymerase chain reaction. Leuk Lymphoma. 2010;51(3):558-561.

Klamova H, Faber E, Zackova D, et al. Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic. Neoplasma. 2010;57(4):355-359.

Polakova KM, Polivkova V, Rulcova J, et al. Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis. Exp Hematol. 2010;38(1):20-26.

Racil Z, Razga F, Buresova L, et al. The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population. Am J Hematol. 2010;85(7):525-528.

White HE, Matejtschuk P, Rigsby P, et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood. 2010;116(22):e111-117.


Doubek M, Palasek I, Pospisil Z, et al. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression. Exp Hematol. 2009;37(6):659-672.

Dvorakova D, Lengerova M, Pospisilova J, Palasek I, Mayer J. A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations. Leukemia. 2009;23(4):793-796.

Eiselleova L, Matulka K, Kriz V, et al. A complex role for FGF-2 in self-renewal, survival, and adhesion of human embryonic stem cells. Stem Cells. 2009;27(8):1847-1857.

Janikova A, Mayer J, Kren L, et al. The persistence of t(14;18)-bearing cells in lymph nodes of patients with follicular lymphoma in complete remission: the evidence for 'a lymphoma stem cell'. Leuk Lymphoma. 2009;50(7):1102-1109.

Razga F, Dvorakova D, Jurcek T, Jeziskova I, Kristkova Z, Mayer J. CEBPA gene mutational status: a complete screening using high-resolution melt curve analysis. Mol Diagn Ther. 2009;13(3):195-200.

Křístková, Z., Dvořáková, D., Rázga, F., Pospíšilová, J., Kujíčková, J., Doubek, M., Mayer, J.: Detekce mutace JAK2V617F u myeloproliferativních onemocnění-přehled a vlastní zkušenosti. Transfuze Hematol. dnes, 2009; 15, 143-147.

Gazdová, J., Dvořáková, D., Ježíšková, I., Rázga, F., Jurček, T., Mayer, J.: Úloha FLT3 mutací v patogenezi akutní myeloidní leukémie. Transfuze Hematol. dnes, 2009; 15, 229-236.


Hrncirova K, Lengerova M, Kocmanova I, et al. Comparison of four methods for efficient isolation of Aspergillus DNA from peripheral blood samples. Klin Mikrobiol Infekc Lek. 2008;14(3):93-99.

Malcikova J, Smardova J, Pekova S, et al. Identification of somatic hypermutations in the TP53 gene in B-cell chronic lymphocytic leukemia. Mol Immunol. 2008;45(5):1525-1529.

Racil Z, Mayer J, Kocmanova I, et al. [Invasive aspergillosis in hematooncological patients: advantages and disadvantages of various diagnostic methods, treatment options and financial costs of therapy]. Vnitr Lek. 2008;54(2):157-168.

Schwarz J, Koristek Z, Stary J, et al. [Therapy of acute promyelocytic leukemia in Czechia: results and analysis of prognostic factors]. Vnitr Lek. 2008;54(7-8):757-770.


Belada D, Smolej L, Stepankova P, et al. [Achieving Bcl-2/IgH negativity in peripheral blood/bone marrow after therapy implies better prognosis for patients with follicular lymphoma]. Vnitr Lek. 2007;53(10):1057-1063.

Janikova-Oborilova A, Mayer J, Dvorakova D, et al. [Practical aspects and clinical value of t(14;18) monitoring in peripheral blood of the follicular lymphoma patients]. Cas Lek Cesk. 2007;146(4):374-381; discussion 381-372.

Janíková A., Mayer J., Křen L.,Kroupová I., Šmardová J., Dvořáková D., et al.: Stanovení t(14;18) z punkční biopsie uzliny u folikulárního lymfomu a význam tzv. molekulární uzlinové remise. Trans. Hemat. dnes, 13, 2: 79-87, 2007

Lengerova M, Racil Z, Hrncirova K, et al. [Detection of invasive aspergillosis by PCR and real-time PCR--benefits and drawbacks]. Klin Mikrobiol Infekc Lek. 2007;13(5):184-189.

Lengerova M, Racil Z, Volfova P, et al. Real-time PCR diagnostics failure caused by nucleotide variability within exon 4 of the human cytomegalovirus major immediate-early gene. J Clin Microbiol. 2007;45(3):1042-1044.


Brdicka R, Beranek M, Cimburova M, et al. [Frequency view on genome changes testing]. Cas Lek Cesk. 2006;145(2):98-103.

Dvorak P, Dvorakova D, Hampl A. Fibroblast growth factor signaling in embryonic and cancer stem cells. FEBS Lett. 2006;580(12):2869-2874.

Krejci M, Mayer J, Doubek M, et al. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia. Bone Marrow Transplant. 2006;38(7):483-491.

Kuhrova V, Francova H, Klimesova D, et al. [Molecular genetic characterization of chronic lymphocytic leukemia aggressivity in Czech patients: a nucleotide variability of genes coding for heavy chain of immunoglobulin]. Cas Lek Cesk. 2006;145(11):855-858; discussion 859-860.

Trbusek M, Malcikova J, Smardova J, et al. Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment. Leukemia. 2006; 20(6):1159-1161.


Doubek M, Brychtova Y, Berkovcova J, et al. Acute myeloid leukemias with recurrent genetic abnormalities: frequent assessment of minimal residual disease and treatment of molecular relapse with chemotherapy. Leukemia. 2005; 19(5):885-888.

Dvorak P, Dvorakova D, Koskova S, et al. Expression and potential role of fibroblast growth factor 2 and its receptors in human embryonic stem cells. Stem Cells. 2005;23(8):1200-1211.

Lengerova M, Volfova P, Lochmanova J, et al. [Problems of cytomegalovirus diagnostics by real-time polymerase chain reaction.]. Klin Mikrobiol Infekc Lek. 2005;11(6):204-209.

Skapova D, Racil Z, Dvorakova D, Minarikova D, Mayer J. Significance of qualitative PCR detection method for preemptive therapy of cytomegalovirus infection in patients after allogeneic hematopoietic stem cell transplantation -- single-centre experience. Neoplasma. 2005;52(2):137-142.


Skapova D, Racil Z, Dvorakova D, Minarikova D, Mayer J. Significance of qualitative PCR detection method for pre-emptive therapy of cytomegalovirus infection in patients after allogeneic hematopoietic stem cell transplantation--single-centre experience. J Clin Virol. 2004;31(4):310-311.

Dvorak P, Dvorakova D, Doubek M, et al. Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia. Leukemia. 2003;17(12):2418-2425.

Fajkus J, Borsky M, Kunicka Z, et al. Changes in telomerase activity, expression and splicing in response to differentiation of normal and carcinoma colon cells. Anticancer Res. 2003;23(2b):1605-1612.

Hajek R, Koristek Z, Vinklarkova J, et al. Interleukin-2 activation of haematopoietic stem cells. Acta Med Austriaca. 2002;29(2):61-67.

Dvorakova D, Krejci P, Mayer J, Fajkus J, Hampl A, Dvorak P. Changes in the expression of FGFR3 in patients with chronic myeloid leukaemia receiving transplants of allogeneic peripheral blood stem cells. Br J Haematol. 2001;113(3):832-835.

Hajek R, Koristek Z, Vinklarkova J, et al. [Activation of autologous hematopoietic stem cell transplants with interleukin-2]. Cas Lek Cesk. 2001;140(14):430-435.

Krejci P, Dvorakova D, Krahulcova E, et al. FGF-2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemias. Leukemia. 2001;15(2):228-237.

Fajkusova L, Fajkus J, Polackova K, Fulnecek J, Dvorakova D, Krahulcova E. Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173. Blood Cells Mol Dis. 2000;26(3):193-204.

zde může být Vaše reklama logo Zbrojovky Brno logo Lékaři bez hranic


změnit velikost písma

Jihlavská 20, 625 00 Brno
+420 532 23 1111

NIAHOSM ISO 9001:2008 ISO 14001:2001